Breakingviews - Bristol-Myers takes $74 bln bet against the market
NEW YORK (Reuters Breakingviews) - Bristol-Myers Squibb is taking a $74 billion bet against the market. There are good reasons to buy rival oncology giant Celgene. But cost cuts don’t cover the 54 percent premium, and the target’s owners get the financial benefit. Bristol is hoping for luck in the courts and multiple regulatory approvals that Celgene’s shareholders were skeptical of.
